Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer

Mina Georgieva, Joao P. da Silveira Nogueira Lima, Pedro Aguiar, Gilberto de Lima Lopes, Benjamin Haaland

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences